Recent Updates
Recently added Catalysts

BAY2433334

Phase 2

Acute Myocardial Infarction | Small molecule | Cardiovascular |Bayer AG|Trials Updated: Apr 19, 2023

BAY2433334 development status

Highest phase Phase 2
Registered trials 3 across 1 sponsor since Jan 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials3
Total Enrollment4,164

FDA Designations

No designations recorded

BAY2433334 clinical trials

BAY2433334 · 3 trials · 3 indications

Phase 2 3
NCT04304534Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart AttackAcute Myocardial Infarction
COMPLETED1,601 Analytics
NCT04304508Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.Acute Non-cardioembolic Ischemic Stroke
COMPLETED1,808 Analytics
NCT04218266Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.Atrial Fibrillation (AF)
COMPLETED755 Analytics
PHASE2COMPLETED
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Acute Myocardial InfarctionUnlock trial analytics
PHASE2COMPLETED
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
Acute Non-cardioembolic Ischemic StrokeUnlock trial analytics
PHASE2COMPLETED
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Atrial Fibrillation (AF)Unlock trial analytics

Study Endpoints

Primary Endpoints

Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)
From baseline up to 52 weeks

CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause

Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5
From baseline up to 52 weeks

Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.

Efficacy-Number of Participants With Composite of Symptomatic Ischemic Stroke or Covert Brain Infarcts Detected by Magnetic Resonance Imaging (MRI)
From baseline up to 26 weeks

Ischemic stroke was defined as either of : 1) Rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\>24 hours symptoms/signs) or imaging evidence of infarction that was not attributable to a non-ischemic cause; 2) Acute worsening of an existing focal neurological deficit that was judged to be attributable to a new infarction or extension of the previous infarction in the same vascular territory, based on persisting symptoms/signs or imaging evidence of infarction and no evidence of a non-ischemic etiology. If imaging was inconclusive, persistent symptoms/signs must be significant (worsening of NIHSS score of 4 or more) and sustained (duration of ≥24 hours or until death). Covert brain infarcts were defined as incident infarcts detected by serial MRI in the absence of an adjudicated stroke consistent with the location of the infarct. MRI criteria for brain infarction were available in the MRI procedures manual.

Safety-Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding
From baseline up to 52 weeks

ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

Secondary Endpoints

Efficacy - Number of Participants With CV Death
From baseline up to 52 weeks
Efficacy - Number of Participants With MI
From baseline up to 52 weeks
Efficacy - Number of Participants With Stroke
From baseline up to 52 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
BAY 2433334 high doseEXPERIMENTAL -
BAY 2433334 medium doseEXPERIMENTAL -
BAY 2433334 low doseEXPERIMENTAL -
BAY2433334 matching placeboPLACEBO_COMPARATOR -
BAY2433334 high doseEXPERIMENTAL -
BAY2433334 medium doseEXPERIMENTAL -
BAY2433334 low doseEXPERIMENTAL -
BAY2433334 50mg+Apixaban matching placeboEXPERIMENTAL -
BAY2433334 20mg+Apixaban matching placeboEXPERIMENTAL -
BAY2433334 matching placebo+ApixabanACTIVE_COMPARATORApixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.

Interventions

NameTypeDescription
BAY2433334DRUGTablet, taken orally once a day.
BAY2433334 matching placeboOTHERTablet, taken orally once a day.
ApixabanDRUGCapsule, taken orally twice a day.
Apixaban matching placeboOTHERCapsule, taken orally twice a day.
Unlock Study Design Details

Eligibility Criteria

Age Range45 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites160

Inclusion Criteria: * Participants must be 45 years of age or older, at the time of signing the informed consent * Acute myocardial infarction (excluding MI associated with PCI or CABG revascularization procedures) with: * clinical symptoms of acute myocardial infarction AND * elevated biomark...

Countries:United StatesAustriaBelgiumCzechiaGermanyHungaryItalyJapanNetherlandsPolandSpainSwedenSwitzerlandUnited KingdomAustraliaBulgariaChinaDenmarkFinlandFrancePortugalRussiaSlovakiaCanadaLatvia
Unlock Eligibility Criteria

Frequently asked questions about BAY2433334

What is BAY2433334 used for?

BAY2433334 is an investigational oral small molecule being studied for cardiovascular conditions including atrial fibrillation, acute non-cardioembolic ischemic stroke, and acute myocardial infarction. It is a Factor XIa inhibitor under development by Bayer AG. The drug is currently in Phase 2 clinical trials and is not yet approved for any use.

What does BAY2433334 target?

BAY2433334 targets Factor XIa, a protein involved in blood clotting. By inhibiting Factor XIa, the drug aims to reduce thrombus formation while potentially lowering bleeding risk compared to other anticoagulants. This mechanism is being evaluated in patients with atrial fibrillation, recent ischemic stroke, and acute myocardial infarction.

Who makes BAY2433334?

BAY2433334 is being developed by Bayer AG, a German pharmaceutical company traded on the OTC market under the ticker BAYRY. Bayer is conducting Phase 2 clinical trials to evaluate the drug's safety and proper dosing in cardiovascular indications.

What phase is BAY2433334 in?

BAY2433334 is in Phase 2 clinical development. All three completed Phase 2 trials have finished, and the drug remains investigational. It has not received FDA approval and is not yet available commercially. Further studies would be needed to advance it to later stages.

What clinical trials is BAY2433334 in?

BAY2433334 has been studied in three completed Phase 2 trials: NCT04218266 in atrial fibrillation with 755 participants, NCT04304508 in acute non-cardioembolic ischemic stroke with 1808 participants, and NCT04304534 in acute myocardial infarction with 1601 participants. All were randomized, double-blind, placebo-controlled studies.

Is BAY2433334 the same as BAY 2433334?

Yes, BAY2433334 and BAY 2433334 refer to the same investigational drug. The name is written with or without a space in clinical trial registries and publications. It is an oral Factor XIa inhibitor being developed by Bayer AG for cardiovascular indications.